Nav: Home

MERS virus in camels: Different variations and a vaccine

December 17, 2015

In light of recent outbreaks of Middle East Respiratory Syndrome coronavirus (MERS-CoV), two studies provide new insights into this life-threatening pathogen, with the first identifying five different lineages of the virus that have circulated between humans and camels, and the second evaluating a MERS-CoV vaccine for camels that could work as a preemptive measure to reduce the pathogen's spread. Over the past three years, several MERS outbreaks have been reported in the Middle East and most recently in South Korea, with a fatality rate of roughly 35%. These outbreaks renew concerns about potential changes in the mode of transmission of this virus. Arabian camels are a common host for MERS-CoV, and one of the most likely sources of human infection; in these animals, the virus can diversify and then be passed to people, though little is known about how the MERS-CoV is evolving in this animal reservoir, or about its prevalence there and the route by which it is transmitted to humans. To gain more insights, Jamal Sabir et al. took samples from more than 1,300 camels in Saudi Arabia, the country most affected by MERS, between May 2014 and April 2015. The overall rate of MERS-CoV among this sample was 12%. Using genetic sequencing, the researchers identified five different lineages of MERS-CoVs, all of which contained human and camel MERS-CoV sequences, indicating that there is a low barrier for interspecies transmission. The wide range of CoVs and their aptitude for infecting multiple species suggests that more variations will emerge in the future. Although changes in human population density, climate conditions, and social factors may contribute to the spread of MERS-CoVs in other regions, such as the recent outbreak in South Korea, the prevention of transmission at the animal-human interface is likely to be the most efficient measure to contain the threat from this virus, the authors conclude.

In a second study, Bart Haagmans et al. tested the efficacy of a vaccine expressing the MERS-CoV spike protein in Arabian camels, using a modified poxvirus as the delivery method. After administering the vaccine both nasally and intramuscularly, all camels developed detectable levels of antibodies against MERS-CoV within three weeks. Upon infection with the virus, these MERS-CoV-vaccinated camels experienced only mild clinical symptoms and were found to have significantly lower levels of the virus compared to controls. The level of protection in MERS-Cov vaccinated camels correlated with levels of neutralizing antibodies they harbored. Since the vaccine uses a modified camelpox virus, vaccinated camels also experienced increased antibodies and protection against this pathogen, which commonly infects Arabian camels, as well.

American Association for the Advancement of Science

Related Antibodies Articles:

Researchers discover first human antibodies that work against all ebolaviruses
After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.
New method enables creation of better therapeutic antibodies
Researchers from the University of Maryland and Rockefeller University have refined a method to modify an antibody's sugar group structure, which plays a large role in determining an antibody's ability to activate the immune response.
Antibodies as 'messengers' in the nervous system
Antibodies are able to activate human nerve cells within milliseconds and hence modify their function -- that is the surprising conclusion of a study carried out at Human Biology at the Technical University of Munich (TUM).
Turning therapeutic antibodies inside-out to fight cancer
Researchers at the University of California, Riverside have camels and llamas to thank for their development of a new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs).
Zika antibodies from infected patient thwart infection in mice
Researchers have identified neutralizing antibodies against Zika virus from an infected patient that fully protected mice from infection, adding to the current arsenal of antibodies in development for much needed antiviral therapies and vaccines.
A review on the therapeutic antibodies for spinal cord injury
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities.
Training human antibodies to protect against HIV
During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection.
How antiviral antibodies become part of immune memory
Emory scientists probe activated B cells, important for forming immune memory, during flu vaccination and infection and Ebola infection in humans.
Mouse antibodies pinpoint Zika's weak spots
Antibodies that specifically protect against Zika infection have been identified in mice, report Washington University School of Medicine in St.
Antibodies identified that thwart Zika virus infection
Scientists at Washington University School of Medicine in St. Louis have identified antibodies capable of protecting against Zika virus infection, a significant step toward developing a vaccine, better diagnostic tests and possibly new antibody-based therapies.

Related Antibodies Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...